跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SARCLISA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SARCLISA
Authorized
STANDARD
SARCLISA
sanofi-aventis canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
aaeb00899ab666e7
Company
sanofi-aventis canada inc
Type
Standard
Approval Details
Approval Id
aaeb00899ab666e7
Drug Approval Canada Name
SARCLISA
Product Name
SARCLISA
Status
Marketed
Status Date
2020-07-03
Original Market Date
2020-07-03
Din
02498243
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Prescription , Schedule D
Ahfs
10:00.00
Atc Original
L01FC02 ISATUXIMAB
Atc Name
l 01 fc 02
Aig Number
0162194001
Company Name
sanofi-aventis canada inc
Company Address
1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4
Active Ingredients
ISATUXIMAB
500 MG / 25 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
aaeb00899ab666e7
Type
Standard
Back to Health Canada Approvals